This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
Entera Bio Ltd. develops pharmaceutical products for human use, a process that involves animal testing as part of preclinical research and regulatory compliance. The company’s public disclosures confirm the use of animal models in its development pipeline.
The company’s website explicitly states that its lead product candidate, a formulation of parathyroid hormone (PTH), was advanced based on data from animal testing. This places the company within the broad pharmaceutical and biotechnology sector where animal experimentation is a standard, integral component of the product development pathway.
While specific details on the scale or nature of the animal testing are not provided in the gathered evidence, the company’s acknowledgment of the practice aligns it with the exclusion criterion for commercial exploitation of animals not covered by more specific sub-categories like animal testing for cosmetics.
Entera Bio Ltd. is a clinical-stage biotechnology company developing oral peptide therapeutics. Its drug development pipeline relies on animal testing as a required component of preclinical research and regulatory compliance. The company explicitly states that its development process includes “preclinical laboratory tests, animal studies and formulation studies all performed in accordance with the FDA’s Good Laboratory Practice (GLP) regulations.” This indicates animal testing is integral to its product development pathway for regulatory submissions to agencies like the FDA.
The company’s lead drug candidate, EB613 for osteoporosis, is an oral formulation of parathyroid hormone (PTH). Published preclinical research for this class of therapy typically involves animal models to assess bone density and pharmacokinetics. As a pharmaceutical developer, Entera Bio commissions, funds, and relies on data from animal studies, whether conducted in-house or outsourced to contract research organizations (CROs), to advance its clinical programs.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.